Drug Response Profiling at KIYATEC

Complex Co-Culture Model Development

Learn about the world’s most advanced ex vivo immuno-oncology models.

Drug Response Profiling Services

3D cell culture service offerings & in vitro model development

Predicting Clinical Response

Learn more about our clinically relevant, predictive 3D response assays

KIYATEC Brochures & Posters

Recent News

3 Posters @ AACR 2017 in DC

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2017 AACR Conference in Washington D.C. KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference. GREENVILLE, SC, March 21, 2017– KIYATEC Inc. is pleased to announce that three abstracts have

Read More

KIYATEC & Mayo Clinic Collaborate to Fight Ovarian Cancer

Tags : 

KIYATEC AND MAYO CLINIC COLLABORATE TO FIGHT OVARIAN CANCER Collaboration aims to validate the accuracy ex vivo 3D (EV3D) cell culture predictions against ovarian cancer patient outcomes Greenville, S.C. | June 16, 2016 07:00 EDT – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic to

Read More

KIYATEC Announces Inaugural SAB Members

Tags : 

KIYATEC Announces Inaugural Scientific Advisory Board Members Experts to Provide Invaluable Insight and Guidance to Advance Predictive Cancer Diagnostics. Members:  Carlos L. Arteaga, MD (Vanderbilt University), David Kaplan, PhD (Tufts University), Anil Sood, MD (MD Anderson) Greenville, S.C. | April 4, 2016 – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced the

Read More

3 KIYATEC Posters @AACR 2016

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2016 AACR Conference in New Orleans KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference. GREENVILLE, SC, March 21, 2016– KIYATEC Inc. is pleased to announce that three abstracts

Read More

NCI Contract: Cancer Stem Cell / Lung Cancer Project

Tags : 

National Cancer Institute (NCI) Awards KIYATEC $1.725M to Develop Cancer Stem Cell (CSC) Expansion Technology  Contract Funds 3D Cell Culture Technology Platform to Expand CSCs for Small Cell Lung Cancer (SCLC) Model Development GREENVILLE, SC | October 22, 2015 – KIYATEC announced today the award of a Fast Track Phase I and Phase II Small Business Innovation Research (SBIR)

Read More

Learn More About KIYATEC

x Shield Logo
This Site Is Protected By
The Shield →